B. Tong

Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer.

E. Perez, L. Dirix, S. Hurvitz, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I Studies of Interleukin (IL)-2 and Rituximab in B-Cell Non-Hodgkin’s Lymphoma

A. Difrancesco, J. Gockerman, A. Levine, 2004, Clinical Cancer Research.

Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody–drug conjugate in development for the treatment of HER2-positive cancer

Dan Lu, Amita Joshi, Patricia M. LoRusso, 2012, Cancer Chemotherapy and Pharmacology.

5001 ORAL Trastuzumab Emtansine (T-DM1) Vs Trastuzumab Plus Docetaxel (H+T) in Previously-untreated HER2-positive Metastatic Breast Cancer (MBC): Primary Results of a Randomized, Multicenter, Open-label Phase II Study (TDM4450g/BO21976)

E. Perez, L. Dirix, L. Gianni, 2011 .

Efficacy and Safety of Lampalizumab for Geographic Atrophy Due to Age-Related Macular Degeneration: Chroma and Spectri Phase 3 Randomized Clinical Trials

Srinivas R. Sadda, Emily Y. Chew, Paul Mitchell, 2018, JAMA ophthalmology.

Challenges with overall survival as an endpoint for efficacy assessment in first line metastatic breast cancer randomized controlled clinical trials and the investigation of truncated overall survival as an alternative endpoint

H. Burger, L. Kaiser, A. Strasak, 2014, memo - Magazine of European Medical Oncology.